Century Therapeutics’ $160-million Series C Financing

Brown Rudnick LLP advised lead investor Casdin Capital and a syndicate of new investors, while White & Case LLP advised Qatar Investment Authority on the deal.

Century Therapeutics announced a $160-million Series C financing. The syndicate included Fidelity Management & Research LLC, the Federated Hermes Kauffmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital. Founding investors Versant Ventures and Leaps by Bayer also participated. Eli Casdin, Founder and Chief Investment Officer of Casdin Capital will be joining the Century Therapeutics Board of Directors.

Century Therapeutics is a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology. Casdin Capital is an investment firm positioned to capitalize on an underappreciated, disruptive technology shift now unfolding in the life sciences and healthcare industry. Casdin’s investments stretch the entire healthcare continuum and into sectors such as agriculture, industrial manufacturing, and traditional information technology.

The Brown Rudnick deal team was led by Adam Schoen (Picture) and Dean Ramanathan.

The White & Case team which advised Qatar Investment Authority on the transaction was led by partner Gary Silverman (Chicago) and included partners Charles Larsen, Anita Varma (both Boston), Michiel Visser (New York) and Andrew Kreisberg (Los Angeles), and associates David Smith (Frankfurt), Matthew Sieben (Chicago), Michelle Ife Irukera, Robin Heszkel and Ilan Har-El (all New York).

Involved fees earner: Dean Ramanathan – Brown Rudnick; Adam Schoen – Brown Rudnick; Ilan Har-El – White & Case; Robin Heszkel – White & Case; Andrew Kreisberg – White & Case; Charles Larsen – White & Case; Gary Silverman – White & Case; David Smith – White & Case; Anita Varma – White & Case; Michiel Visser – White & Case;

Law Firms: Brown Rudnick; White & Case;

Clients: Casdin Capital; Federated Hermes; Fidelity Management & Research Company; Logos Capital; Marshall Wace; Octagon Capital; OrbiMed; Qatar Investment Authority; RA Capital Management;

Author: Martina Bellini